Stevens Capital Management LP Makes New Investment in Hologic, Inc. (NASDAQ:HOLX)

Stevens Capital Management LP bought a new position in shares of Hologic, Inc. (NASDAQ:HOLX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 11,283 shares of the medical equipment provider’s stock, valued at approximately $806,000.

A number of other large investors have also modified their holdings of HOLX. Qube Research & Technologies Ltd grew its holdings in shares of Hologic by 117.2% in the third quarter. Qube Research & Technologies Ltd now owns 1,378,258 shares of the medical equipment provider’s stock valued at $95,651,000 after purchasing an additional 743,557 shares during the period. Jennison Associates LLC purchased a new stake in shares of Hologic in the fourth quarter valued at about $30,079,000. Assenagon Asset Management S.A. grew its holdings in shares of Hologic by 90.4% in the third quarter. Assenagon Asset Management S.A. now owns 845,493 shares of the medical equipment provider’s stock valued at $58,677,000 after purchasing an additional 401,486 shares during the period. Victory Capital Management Inc. lifted its position in Hologic by 8.9% in the third quarter. Victory Capital Management Inc. now owns 4,838,090 shares of the medical equipment provider’s stock valued at $335,763,000 after buying an additional 393,371 shares during the last quarter. Finally, Clearbridge Investments LLC acquired a new position in Hologic in the third quarter valued at about $25,398,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. UBS Group upped their target price on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research report on Friday, February 2nd. William Blair reissued an “outperform” rating on shares of Hologic in a research report on Friday, February 2nd. StockNews.com lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Friday, March 8th. Evercore ISI increased their price target on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. Finally, Raymond James raised their target price on shares of Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a research report on Friday, February 2nd. Six investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Hologic currently has a consensus rating of “Hold” and a consensus target price of $87.00.

Insider Buying and Selling at Hologic

In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the sale, the director now owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the sale, the director now owns 1,572 shares in the company, valued at approximately $119,802.12. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the sale, the director now owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 32,846 shares of company stock valued at $2,473,443. 1.75% of the stock is owned by company insiders.

Hologic Stock Performance

NASDAQ:HOLX traded down $1.00 during midday trading on Thursday, reaching $75.71. The stock had a trading volume of 1,190,936 shares, compared to its average volume of 1,779,627. The firm has a fifty day simple moving average of $75.95 and a two-hundred day simple moving average of $72.72. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $87.88. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55. The stock has a market cap of $17.77 billion, a P/E ratio of 36.36, a P/E/G ratio of 2.61 and a beta of 1.00.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $989.32 million. During the same period last year, the firm posted $1.07 EPS. Hologic’s quarterly revenue was down 5.7% on a year-over-year basis. On average, equities analysts expect that Hologic, Inc. will post 4.01 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.